Ribupatide
A Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Tablets in Overweight or Obese Subjects
Fujian Shengdi Pharmaceutical Co · Phase 3 · Recruiting · Enrollment 675
| Arm | Nausea | Vomiting | Diarrhea | Discontinuation | Deaths |
|---|---|---|---|---|---|
| HRS9531 Tablet Group | n/r | n/r | n/r | n/r | n/r |
| HRS9531 Tablet Placebo Group | n/r | n/r | n/r | n/r | n/r |
A count stays a count. This page does not turn a count into a percent.